nference Closes $60 Million Series B Financing to Advance Its Augmented Intelligence Platform for Clinical Research and Therapeutic Development
Summary
CAMBRIDGE, Mass.--(BUSINESS WIRE)--nference today announced the completion of a $60 million Series B round to advance its biomedical knowledge synthesis platform. “ Our platform makes the predominantly unstructured health information such as clinical notes, case reports, scientific literature, pathology images, ECG waveforms and genomic sequences computable,” said Murali Aravamudan, Founder and Chief Executive Officer of nference. “ Causal inference of genotype-phenotype relationships necessitate such triangulation-at-scale across differentiated bodies of biomedical knowledge.” “ We are thrilled to amplify the impact of data science with our biopharmaceutical partners who leverage our platform in order to pursue a broad spectrum of therapeutics and digital health applications to benefit patients,” said Venky Soundararajan, Ph.D., Founder and Chief Scientific Officer of nference. nference uses state-of-the-art neural networks (shallow and deep learning models) for real-time, automated extraction of insights from the scientific, clinical, regulatory and commercial data sets. nference is making biomedical knowledge computable, and building its AI platform to serve as the connective fabric for various silos of information that exist in unstructured, semi-structured, and structured forms across health care enterprises.